- Home
- RMMZ vs THTX Comparison
RMMZ vs THTX Comparison
Compare RMMZ & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- THTX
- Stock Information
- Founded
- RMMZ 2022
- THTX 1993
- Country
- RMMZ United States
- THTX Canada
- Employees
- RMMZ N/A
- THTX N/A
- Industry
- RMMZ Investment Managers
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- THTX Health Care
- Exchange
- RMMZ Nasdaq
- THTX Nasdaq
- Market Cap
- RMMZ 122.3M
- THTX 144.8M
- IPO Year
- RMMZ N/A
- THTX N/A
- Fundamental
- Price
- RMMZ $14.94
- THTX $3.31
- Analyst Decision
- RMMZ
- THTX Hold
- Analyst Count
- RMMZ 0
- THTX 1
- Target Price
- RMMZ N/A
- THTX N/A
- AVG Volume (30 Days)
- RMMZ 25.6K
- THTX 416.1K
- Earning Date
- RMMZ 01-01-0001
- THTX 10-09-2025
- Dividend Yield
- RMMZ 7.33%
- THTX N/A
- EPS Growth
- RMMZ N/A
- THTX N/A
- EPS
- RMMZ 0.82
- THTX N/A
- Revenue
- RMMZ N/A
- THTX $84,378,000.00
- Revenue This Year
- RMMZ N/A
- THTX N/A
- Revenue Next Year
- RMMZ N/A
- THTX $13.76
- P/E Ratio
- RMMZ $19.41
- THTX N/A
- Revenue Growth
- RMMZ N/A
- THTX 2.19
- 52 Week Low
- RMMZ $12.92
- THTX $1.12
- 52 Week High
- RMMZ $16.99
- THTX $3.34
- Technical
- Relative Strength Index (RSI)
- RMMZ 63.32
- THTX 74.67
- Support Level
- RMMZ $14.85
- THTX $3.26
- Resistance Level
- RMMZ $14.87
- THTX $3.34
- Average True Range (ATR)
- RMMZ 0.18
- THTX 0.02
- MACD
- RMMZ 0.01
- THTX -0.00
- Stochastic Oscillator
- RMMZ 70.71
- THTX 73.80
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.